← Eichor
Study identifier: NCT05825261 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Exploring Novel Biomarkers for Emphysema Detection

Condition: Copd · Emphysema  ·  Sponsor: Maastricht University

PhaseN/A
Planned participants200
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this clinical trial is to evaluate whether voice or capnometry, alone or in combination with other (non invasive) biomarkers can be used to detect emphysema on chest CT-scan in people with chronic obstructive pulmonary disease (COPD). The main question it aims to answer is: • Can a machine-learning based algorithm be developed that can classify the extent of emphysema on chest CT scan from patients with COPD, based on voice and/or capnometry. Participants will: * perform different voice-related tasks * perform capnometry twice (before/after exercise) * perform a light exercise task between tasks ( 5-sit-to-stand test) * undergo one venipuncture

This description comes directly from the study's public registry record.

Talk to the study team

Sami Simons, MD PhD  ·  +31 043 3876543  ·  sami.simons@mumc.nl

Always discuss trial participation with your own doctor first.

Locations (2)

Dept of Respiratory Medicine, Maastricht University Medical CentreMaastricht, Limburg, NetherlandsRecruiting
Laurentius ZiekenhuisRoermond, Limburg, NetherlandsNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05825261